352
Participants
Start Date
July 31, 2025
Primary Completion Date
June 30, 2030
Study Completion Date
July 31, 2030
PCSK9 inhibitor
Single dose of subcutaneous administration of PCSK9 inhibitors (evolocumab) after PCI in patients with coronary artery disease and elevated post-PCI lipid core burden (maxLCBI4mm ≥ 200).
Standard Lipid-Lowering Therapy
Lipid-lowering therapy with high-intensity or maximally tolerated statins with or without ezetimibe, as per current clinical guidelines, excluding the use of PCSK9 inhibitors.
DOTTER Inc.
UNKNOWN
Hanyang University Seoul Hospital
OTHER